Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6124)
All Articles published online
|
Publishing Process of This Article
|
Jul 28, 2014 (publication date) through Jan 11, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Radiology
ISSN
1949-8470
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | van Gool MH, Aukema TS, Hartemink KJ, Valdés Olmos RA, van Tinteren H, Klomp HM. FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC. World J Radiol 2014; 6(7): 392-398 [PMID: 25071879 DOI: 10.4329/wjr.v6.i7.392] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8470/full/v6/i7/392.htm |
| Number | Citing Articles |
| 1 |
Karim Amrane, Luca Campedel, Coline Le Meur, Ronan Abgral, Dris Kharroubi, Jacques Cadranel. Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.691253
|
| 2 |
Amit Bhoil. Lesion Analysis in PERCIST 1.0: Clinical Ease versus Research Requisite—Where Does the Balance Exist?. World Journal of Nuclear Medicine 2023; 22(02): 100 doi: 10.1055/s-0042-1750406
|
| 3 |
Sébastien Dejust, Abdenasser Moubtakir, Alain Prevost, Khadija El Farsaoui, David Morland. 18F-FDG PET/CT Evaluation of Crizotinib and Lorlatinib Therapy in Metastatic ROS-1–Positive Non–Small Cell Lung Cancer. Clinical Nuclear Medicine 2020; 45(3): 209 doi: 10.1097/RLU.0000000000002912
|
| 4 |
Keith D Eaton, Perrin E Romine, Renato G Martins, Antoine Leblond, Laurie L Carr, Hubert J Vesselle. Adaptive Fluorodeoxyglucose-Positron Emission Tomography Based Chemotherapy Selection for Metastatic Non-small Cell Lung Cancer. Cureus 2021; doi: 10.7759/cureus.18804
|
| 5 |
Anastasios Dimou, Carol Sherman, John Wrangle. Imaging in Advanced Non–Small Cell Lung Cancer. Journal of Thoracic Imaging 2016; 31(4): 238 doi: 10.1097/RTI.0000000000000219
|
| 6 |
Vadim Bernard-Gauthier, Justin Bailey, Sheldon Berke, Ralf Schirrmacher. Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging. Molecules 2015; 20(12): 22000 doi: 10.3390/molecules201219816
|
| 7 |
Yu-Hung Chen, Tso-Fu Wang, Sung-Chao Chu, Chih-Bin Lin, Ling-Yi Wang, Kun-Han Lue, Shu-Hsin Liu, Sheng-Chieh Chan, Domenico Albano. Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma. PLOS ONE 2020; 15(12): e0244502 doi: 10.1371/journal.pone.0244502
|
| 8 |
Yu-Erh Huang, Ying-Huang Tsai, Yu-Jie Huang, Jr-Hau Lung, Kuo-Wei Ho, Tzu-Chen Yen, Sheng-Chieh Chan, Shu-Tian Chen, Ming-Feng Tsai, Ming-Szu Hung. 18F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs. Cancers 2022; 14(6): 1507 doi: 10.3390/cancers14061507
|
| 9 |
G. Fernández Pérez, R. Sánchez Escribano, A.M. García Vicente, A. Luna Alcalá, J. Ceballos Viro, R.C. Delgado Bolton, J.C. Vilanova Busquets, P. Sánchez Rovira, M.P. Fierro Alanis, R. García Figueiras, J.E. Alés Martínez. Guía SEOM-SERAM-SEMNIM sobre el empleo de las técnicas de imagen funcional y molecular en el cáncer de pulmón no microcítico avanzado. Radiología 2018; 60(4): 332 doi: 10.1016/j.rx.2018.01.007
|
| 10 |
Silvia Valtorta, Massimo Moro, Giovanna Prisinzano, Giulia Bertolini, Monica Tortoreto, Isabella Raccagni, Ugo Pastorino, Luca Roz, Gabriella Sozzi, Rosa Maria Moresco. Metabolic Evaluation of Non–Small Cell Lung Cancer Patient–Derived Xenograft Models Using 18F-FDG PET: A Potential Tool for Early Therapy Response. Journal of Nuclear Medicine 2017; 58(1): 42 doi: 10.2967/jnumed.116.176404
|
| 11 |
Laura Valerio, Federica Guidoccio, Carlotta Giani, Elisa Tardelli, Giulia Puccini, Luciana Puleo, Elisa Minaldi, Giuseppe Boni, Rossella Elisei, Duccio Volterrani. [18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival. The Journal of Clinical Endocrinology & Metabolism 2021; 106(8): 2355 doi: 10.1210/clinem/dgab278
|
| 12 |
Xiaofeng Li, Qiang Fu, Yanjia Zhu, Jian Wang, Jianjing Liu, Xiaozhou Yu, Wengui Xu. CD147‐mediated glucose metabolic regulation contributes to the predictive role of 18F‐FDG PET/CT imaging for EGFR‐TKI treatment sensitivity in NSCLC. Molecular Carcinogenesis 2019; 58(2): 247 doi: 10.1002/mc.22923
|
| 13 |
Jing-Wen Bai, Si-Qi Qiu, Guo-Jun Zhang. Molecular and functional imaging in cancer-targeted therapy: current applications and future directions. Signal Transduction and Targeted Therapy 2023; 8(1) doi: 10.1038/s41392-023-01366-y
|
| 14 |
Yun Shi, Yang Shi, Xuli Yang, Jianrong Chen, Qi Qian, Dengfu Yao, Guangzhou Wu. Abnormal expression of VEGF and its gene transcription status as diagnostic indicators in patients with non-small cell lung cancer ⁎. Oncology and Translational Medicine 2015; 1(5): 201 doi: 10.1007/s10330-015-0077-9
|
| 15 |
G. Fernández-Pérez, R. Sánchez-Escribano, A. M. García-Vicente, A. Luna-Alcalá, J. Ceballos-Viro, R. C. Delgado-Bolton, J. C. Vilanova-Busquets, P. Sánchez-Rovira, M. P. Fierro-Alanis, R. García-Figueiras, J. E. Alés-Martínez. SEOM–SERAM–SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer. Clinical and Translational Oncology 2018; 20(7): 837 doi: 10.1007/s12094-017-1795-y
|
| 16 |
Dayu Xu, Fan Yu, Tiantian Guo, Yue Zhou, Jinmeng Zhang, Yida Li, Shanshan Jiang, Jiuang Mao, Xi Yang, Li Chu, Xiao Chu, Shengping Wang, Jianjiao Ni, Zhengfei Zhu. Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons. The British Journal of Radiology 2022; 95(1136) doi: 10.1259/bjr.20220035
|
| 17 |
Wolfgang Mohnike, Gustav Hör, Andreas Hertel. PET/CT-Atlas. 2016; : 99 doi: 10.1007/978-3-662-48842-3_6
|
| 18 |
Sandip Basu, Rakesh Kumar, Rohit Ranade. Assessment of Treatment Response Using PET. PET Clinics 2015; 10(1): 9 doi: 10.1016/j.cpet.2014.09.002
|
| 19 |
Kazuhiro Kitajima, Hiroshi Doi, Tomonori Kanda, Tomohiko Yamane, Tetsuya Tsujikawa, Hayato Kaida, Yukihisa Tamaki, Kozo Kuribayashi. Present and future roles of FDG-PET/CT imaging in the management of lung cancer. Japanese Journal of Radiology 2016; 34(6): 387 doi: 10.1007/s11604-016-0546-2
|
| 20 |
Qingjie Ma, Kaiyin Min, Ting Wang, Bin Chen, Qiang Wen, Fan Wang, Tiefeng Ji, Shi Gao. 99mTc-3PRGD2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab. Annals of Nuclear Medicine 2015; 29(6): 519 doi: 10.1007/s12149-015-0975-5
|
| 21 |
Chul Kim, Stephen V. Liu, Jennifer Crawford, Tisdrey Torres, Vincent Chen, Jillian Thompson, Ming Tan, Giuseppe Esposito, Deepa S. Subramaniam, Giuseppe Giaccone. A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.728155
|
| 22 |
A.F. Scarsbrook, S.F. Barrington. PET-CT in the UK: current status and future directions. Clinical Radiology 2016; 71(7): 673 doi: 10.1016/j.crad.2016.02.023
|
| 23 |
Marta Cremonesi, Laura Gilardi, Mahila Esmeralda Ferrari, Gaia Piperno, Laura Lavinia Travaini, Robert Timmerman, Francesca Botta, Guido Baroni, Chiara Maria Grana, Sara Ronchi, Delia Ciardo, Barbara Alicja Jereczek-Fossa, Cristina Garibaldi, Roberto Orecchia. Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review. European Journal of Nuclear Medicine and Molecular Imaging 2017; 44(11): 1915 doi: 10.1007/s00259-017-3762-9
|
| 24 |
Lavinia Tan, Benjamin Solomon. Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment. PET Clinics 2018; 13(1): 33 doi: 10.1016/j.cpet.2017.08.004
|
| 25 |
Marko Magdi Abdou Sidrak, Maria Silvia De Feo, Viviana Frantellizzi, Andrea Marongiu, Salvatore Caponnetto, Luca Filippi, Susanna Nuvoli, Angela Spanu, Orazio Schillaci, Giuseppe De Vincentis. First-, Second-, and Third-Generation Radiolabeled Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Positron Emission Tomography: State of the Art, a Systematic Review. Cancer Biotherapy and Radiopharmaceuticals 2023; 38(4): 232 doi: 10.1089/cbr.2022.0049
|
| 26 |
Bouhari Altine, Yongkang Gai, Na Han, Yaqun Jiang, Hao Ji, Hanyi Fang, Alexandre Niyonkuru, Khamis Hassan Bakari, Maher Mohamad Rajab Arnous, Qingyao Liu, Yongxue Zhang, Xiaoli Lan. Preclinical Evaluation of a Fluorine-18 (18F)-Labeled Phosphatidylinositol 3-Kinase Inhibitor for Breast Cancer Imaging. Molecular Pharmaceutics 2019; 16(11): 4563 doi: 10.1021/acs.molpharmaceut.9b00690
|
| 27 |
Yansong Lin, Chen Wang, Wen Gao, Ruixue Cui, Jun Liang. Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer. Oncotarget 2017; 8(26): 42252 doi: 10.18632/oncotarget.15036
|
| 28 |
Natalie J. Serkova, S. Gail Eckhardt. Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents. Frontiers in Oncology 2016; 6 doi: 10.3389/fonc.2016.00152
|
| 29 |
Wei Sun, Guifu He, Mingming Zhang, Yi Zhao, Hongmei Yu, Yi Li, Wei Wu, Tiefeng Ji. 99mTc-3PRGD2 SPECT Predicts the Outcome of Endostar and Cisplatin Therapy in Xenograft Animals. Dose-Response 2019; 17(4) doi: 10.1177/1559325819882544
|
| 30 |
Zhaoqi Zhang, Xinming Zhao, Cuimin Ding, Jianfang Wang, Jingmian Zhang, Fan Wang. 99mTc-3PRGD2 SPECT/CT Imaging for Monitoring Early Response of EGFR-TKIs Therapy in Patients with Advanced-Stage Lung Adenocarcinoma. Cancer Biotherapy and Radiopharmaceuticals 2016; 31(7): 238 doi: 10.1089/cbr.2016.2052
|
| 31 |
Rudolf A. Werner, Ralph A. Bundschuh, Takahiro Higuchi, Mehrbod S. Javadi, Steven P. Rowe, Norbert Zsótér, Matthias Kroiss, Martin Fassnacht, Andreas K. Buck, Michael C. Kreissl, Constantin Lapa. Volumetric and texture analysis of pretherapeutic 18F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib. Endocrine 2019; 63(2): 293 doi: 10.1007/s12020-018-1749-3
|
| 32 |
Amanda Tufman, Ullrich Müller-Lisse, Simone Reu, Rudolf Maria Huber, Frank Berger. The relevance of positron emission tomography response in non-small cell lung cancer. memo - Magazine of European Medical Oncology 2015; 8(2): 119 doi: 10.1007/s12254-015-0213-9
|
| 33 |
David Fecher, Elisabeth Hofmann, Andreas Buck, Ralph Bundschuh, Sarah Nietzer, Gudrun Dandekar, Thorsten Walles, Heike Walles, Katharina Lückerath, Maria Steinke, Nils Cordes. Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging. PLOS ONE 2016; 11(8): e0160282 doi: 10.1371/journal.pone.0160282
|